Sunday, December 21, 2014 11:10:28 AM
I'm pretty sure that the answer to your question is "No". In fact, I wasn't able to find any similar statements to this one in any subsequent literature:
"At its optimal production capacity this plant will make 1 kilogram of GMP certificated FluCide/year, which is sufficient to supply 1MM doses of the drug/year".
The issue of the plant's capacity in terms of doses of Flucide just stopped being addressed.
That quote is from the March/April 2012 onemedplace research report. In its December 2011 research report onemediaplace had said this:
"Eventually if FluCide receives marketing approval, this plant
has enough throughput to supply FluCide for 100K-1M adult doses/year."
The December report didn't provide a statement comparable to "At its optimal production capacity this plant will make 1 kilogram of GMP certificated FluCide/year", so we can't tell whether the change from "100K-1M adult doses/year" to "1MM doses of the drug/year" is a function of a change or changes in anticipated dose size or anticipated plant capacity. It seems likely that the company's own answer to your question at that time would have been "No".
I didn't do a side-by-side to see what else may have changed from one report to the next***, but I did see this, which I think you may find important:
"DISCLAIMER: WHILE THE COMPANY IS THE SOURCE OF THE FACTUAL DATA, THE ANALYSES AND INTERPRETATION OF THESE DATA REPRESENT THE WORK OF THE OMP RESEARCH TEAM."
I'm sure no one thought that onemedia made up their facts, but if any of them are in question they have provided their source.
http://www.google.com/search?q=%22flucide+for+100k-1m%22&safe=off&client=safari&rls=en&prmd=ivns&filter=0
***Actually I did see one change.
The December 2011 report said this:
GMP certified manufacturing plant starts making FluCide......1H2013
The March/April 2012 report said:
NNVC management believes this plant will be ready to produce FluCide by YE2012 or 1Q2013
Strangely enough, it seems the company provided an earlier anticipated date for the start of Fluicide production in their update.
"I ated the purple berries"
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM